Abstract
The facultative intracellular pathogen and zoonotic agent Brucella sp. possesses two carbonic anhydrases (CAs, EC 4.2.1.1), termed bsCA I and bsCA II (in Brucella suis), belonging to the β-class of these metalloproteins. These zinc enzymes, present in many other pathogenic bacteria, have been considered recently as potential antibacterial targets. The catalytic activity of bsCA II is higher than that of bsCA I (for the conversion of CO2 to bicarbonate). Both enzymes were inhibited by the well-studied inhibitor acetazolamide, a sulfonamide drug. A library of 41 sulfonamides and one sulfamate, among which were 13 clinically tested drugs, was used for inhibition studies with bsCA I and II. These compounds were generally much more potent inhibitors of bsCA I (KIs of 17-75 nM) than of bsCA II (KIs of 84-923nM). However, certain glycosidic sulfonamide derivatives exhibited the same strong inhibitory activity on both bsCA I and bsCA II (KIs of 8.9-20 nM). Furthermore, at least one of these glycosylsulfonamides showed a significant inhibition of B. suis growth after 8-11 days of culture in minimal medium. In conclusion, as β-CAs of Brucella are susceptible to inhibition by a wide range of aromatic and heteroaromatic sulfonamides, they may represent novel targets for the development of clinically useful antibacterial agents.
Keywords: β-carbonic anhydrase, Brucella suis, inhibition, brucellosis, sulfonamide, zoonotic agent, carbonic anhydrases, metalloproteins, acetazolamide, sulfonamide drug, glycosidic sulfonamide, glycosylsulfonamides, cocco-bacilli, dendritic cells, Helicobacter pylori, Mycobacterium tuberculosis, bsCA I, sulfamate, methazolamide, ethoxzolamide, dichorophenamide, dorzolamide, brinzolamide, benzolamide, topiramate, zonisamide, sulpiride, indisulam, celecoxib, valdecoxib, glycosylsulfonamide
Current Pharmaceutical Design
Title: Brucella Carbonic Anhydrases: New Targets for Designing Anti-Infective Agents
Volume: 16 Issue: 29
Author(s): Jean-Yves Winum, Stephan Kohler and Claudiu T. Supuran
Affiliation:
Keywords: β-carbonic anhydrase, Brucella suis, inhibition, brucellosis, sulfonamide, zoonotic agent, carbonic anhydrases, metalloproteins, acetazolamide, sulfonamide drug, glycosidic sulfonamide, glycosylsulfonamides, cocco-bacilli, dendritic cells, Helicobacter pylori, Mycobacterium tuberculosis, bsCA I, sulfamate, methazolamide, ethoxzolamide, dichorophenamide, dorzolamide, brinzolamide, benzolamide, topiramate, zonisamide, sulpiride, indisulam, celecoxib, valdecoxib, glycosylsulfonamide
Abstract: The facultative intracellular pathogen and zoonotic agent Brucella sp. possesses two carbonic anhydrases (CAs, EC 4.2.1.1), termed bsCA I and bsCA II (in Brucella suis), belonging to the β-class of these metalloproteins. These zinc enzymes, present in many other pathogenic bacteria, have been considered recently as potential antibacterial targets. The catalytic activity of bsCA II is higher than that of bsCA I (for the conversion of CO2 to bicarbonate). Both enzymes were inhibited by the well-studied inhibitor acetazolamide, a sulfonamide drug. A library of 41 sulfonamides and one sulfamate, among which were 13 clinically tested drugs, was used for inhibition studies with bsCA I and II. These compounds were generally much more potent inhibitors of bsCA I (KIs of 17-75 nM) than of bsCA II (KIs of 84-923nM). However, certain glycosidic sulfonamide derivatives exhibited the same strong inhibitory activity on both bsCA I and bsCA II (KIs of 8.9-20 nM). Furthermore, at least one of these glycosylsulfonamides showed a significant inhibition of B. suis growth after 8-11 days of culture in minimal medium. In conclusion, as β-CAs of Brucella are susceptible to inhibition by a wide range of aromatic and heteroaromatic sulfonamides, they may represent novel targets for the development of clinically useful antibacterial agents.
Export Options
About this article
Cite this article as:
Winum Jean-Yves, Kohler Stephan and T. Supuran Claudiu, Brucella Carbonic Anhydrases: New Targets for Designing Anti-Infective Agents, Current Pharmaceutical Design 2010; 16 (29) . https://dx.doi.org/10.2174/138161210793429850
DOI https://dx.doi.org/10.2174/138161210793429850 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Bergenin - A Biologically Active Scaffold: Nanotechnological Perspectives
Current Topics in Medicinal Chemistry New Antibiotics for Severe ICU-Aquired Bacterial Infections
Infectious Disorders - Drug Targets Virulence Factor Targeting of the Bacterial Pathogen Staphylococcus aureus for Vaccine and Therapeutics
Current Drug Targets Infection and Anemia
Infectious Disorders - Drug Targets Acute Decompensated Heart Failure Update
Current Cardiology Reviews Exploring the Biology and Structural Architecture of Sortase Role on Biofilm Formation in Gram Positive Pathogens
Current Topics in Medicinal Chemistry Sutureless Aortic Valve Replacement Using Perceval S Valve
Recent Patents on Cardiovascular Drug Discovery Isolation of <i>Morganella Morganii</i> and <i>Providencia</i> Species from Clinical Samples in a Tertiary Care Hospital in North India
Infectious Disorders - Drug Targets Current Research on Opioid Receptor Function
Current Drug Targets Prevention of Ischemic Stroke: Antithrombotic Therapy in Cardiac Embolism
Current Drug Targets Methylene Blue and Vasoplegia: Who, When, and How?
Mini-Reviews in Medicinal Chemistry Phytochemical Analysis and Antibacterial Action of Indian Traditional Medicinal Plants
Anti-Infective Agents Using PK/PD to Optimize Antibiotic Dosing for Critically Ill Patients
Current Pharmaceutical Biotechnology Editorial [Hot topic:Thromboembolism in Patients with Malignancy (Guest Editor: Ioannis Starakis)]
Cardiovascular & Hematological Disorders-Drug Targets Multiple Drugs Causing Severe Anemia in Infective Endocarditis
Cardiovascular & Hematological Disorders-Drug Targets Small Peptide Radiopharmaceuticals in the Imaging of Acute Thrombus
Current Pharmaceutical Design The Oral Cavity, Biofilms and Ventilator-Associated Pneumonia
Current Respiratory Medicine Reviews Biofilms in Skin Infections: Propionibacterium acnes and Acne Vulgaris
Infectious Disorders - Drug Targets Unusual Clinical Manifestations of the Antiphospholipid Syndrome
Current Rheumatology Reviews Antibiotic Resistance and Microbiota Response
Current Pharmaceutical Design